At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Aug 28, 2026 at 06:17 ET
Teva announced a stalking-horse bid to acquire BioXcel Therapeutics' IGALMI (dexmedetomidine sublingual film) and related assets for $57.5M upfront plus up to $67.5M in contingent payments, through a court-supervised bankruptcy sale. The asset is under FDA review for at-home use in agitation associated with schizophrenia or bipolar disorder, with a PDUFA date of November 14, 2026. If approved, this would be the first FDA-approved at-home treatment for this condition, expanding Teva's psychiatry portfolio.
- Teva is the stalking-horse bidder for BioXcel Therapeutics' IGALMI (dexmedetomidine sublingual film) in a Section 363 bankruptcy sale.
- Upfront payment of $57.5 million plus up to $67.5 million in contingent payments tied to FDA approval timing and sales milestones.
- PDUFA target action date for at-home use approval is November 14, 2026.
- If approved, IGALMI would be the first FDA-approved at-home treatment for agitation associated with schizophrenia or bipolar I/II disorder.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access